Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties, used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Typical maintenance dose is 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **Initiation (2-10 years or weighing <30 kg):** 5 mg once daily.
* **Initiation (≥10 years or weighing ≥30 kg):** 10 mg once daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability. Doses should be administered in a divided regimen twice daily.
* **Maintenance:**
* **2-10 years or weighing <30 kg:** Typical maintenance dose is 5 mg twice daily, with a maximum of 10 mg twice daily (20 mg/day).
* **≥10 years or weighing ≥30 kg:** Typical maintenance dose is 10 mg twice daily, with a maximum of 20 mg twice daily (40 mg/day).
* **Uncertainty:** Dosing in children younger than 2 years has not been established and should be approached with extreme caution, if at all.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, though specific guidelines are not established.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary, though specific guidelines are not established.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, difficulty with coordination, cough, upper respiratory tract infection, pyrexia, fatigue, vomiting, diarrhea.
* **Serious:** Severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), serious and life-threatening respiratory depression, withdrawal symptoms (seizures, tremor, insomnia, anxiety), behavioral changes (suicidal ideation/behavior), dependence and tolerance.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives/hypnotics):** Increased risk of profound sedation, respiratory depression, and coma. Use concomitantly with extreme caution or avoid.
* **CYP1A2 Inhibitors (e.g., fluvoxamine):** May increase clobazam concentrations.
* **CYP2C19 Inhibitors (e.g., omeprazole):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam concentrations.
* **Anticonvulsants:** Potential for additive CNS depression. Monitor for excessive sedation.
## Monitoring
* **Clinical:** Assess for seizure frequency and type, sedation, behavioral changes, and signs of withdrawal.
* **Respiratory:** Monitor respiratory status, especially in patients with pre-existing respiratory conditions or those receiving concomitant respiratory depressants.
* **Dermatologic:** Monitor for rash or other signs of severe skin reactions.
* **Drowsiness:** Counsel patients on potential for drowsiness and advise caution with activities requiring mental alertness.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Taper dose gradually.
* Long-term use may lead to reduced efficacy due to tolerance.
* Due to the risk of somnolence and cognitive impairment, patients should be cautioned about operating heavy machinery or driving.
* Use in elderly patients may require lower initial doses and slower titration due to increased sensitivity to CNS effects.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines for complete details. Dosing may vary based on individual patient factors and local protocols.*
